Newsroom

Dendrogenix is pleased to share that our team will participate in BIO-Europe Spring 2026, taking place in Lisbon from March 23 to 25.

This major European partnering forum gathers key players from the biopharmaceutical ecosystem — from biotech innovators to pharma companies and investors — to spark new collaborations and drive progress in life sciences.

During the event, we will highlight recent advances from our Phase 1/2a clinical trial in patients with age related hearing loss and reduced speech intelligibility in noise.

We will also use this opportunity to connect with potential private investors and partners to support the next stages of our pipeline.

Dendrogenix, an innovative biotechnology company based in Liège (Belgium) announced today positive results from its first Phase 1 clinical trial evaluating its drug candidate DX243. Building on these encouraging data, the company plans to initiate a Phase 2a clinical trial in the first quarter of 2026 in the field of age-related hearing loss (presbycusis).
Located at the heart of the biomedical research ecosystem of CHU Sart-Tilman and GIGA Neuroscience, Dendrogenix is developing a novel proprietary class of compounds called “Dendrogenin”, with DX243 as its first clinical candidate. These compounds are intended for the treatment of neurodegenerative diseases, with a particular focus on age-related auditory disorders.

Phase 1 clinical results: excellent tolerability supporting ...